LumiraDx (NASDAQ:LMDX) continued its commercial expansion of its HbA1c diabetes test for professional use across multiple care settings.
The HbA1c test measures blood sugar levels over the past three months, according to the CDC. The test also helps screen and identify potential at-risk patients for developing diabetes. It produces results in under seven minutes and improves efficiency and convenience with both screening and monitoring.
“As the global prevalence of diabetes is increasing, it’s critical for healthcare professionals to have access to rapid and reliable HbA1c results. The availability of an immediate, lab-comparable HbA1c test has been shown to improve patient outcomes through improved diabetes management. In addition, there are a number of well-known comorbidities associated with diabetes. These are supported through our multi-assay testing Platform – including tests for cardiac biomarkers, coagulation, and inflammation- making the LumiraDx Platform an ideal tool for improving patient outcomes within the community healthcare setting,” said David Walton, chief commercial officer for LumiraDx.
LumiraDX is a biotechnology company focused on point of care diagnostics. Its microfluidic technology offers fast, high performance and accessible diagnostic options. The company’s laboratory offerings include tests on a single portable platform with over 30 assays available. The optional assays include infectious diseases, cardiovascular diseases, diabetes and coagulation disorders.
Formed in 2014 in the United Kingdom, governments and healthcare institutions use its diagnostic testing across laboratories, urgent care, physician offices, pharmacies, schools and workplaces, to help either screen, diagnose and monitor wellness and disease.
Read more: The Mugglehead technology roundup: medical tech and biotechnology edition
Read more: Inspira Technologies gets Israeli patent office nod for key component to Inspira Art system
Every one in 10 adults have diabetes and nearly half of those are undiagnosed, according to the IDF Diabetes Atlas. The LumiraDx Platform allows the LumiraDx HbA1c test to address the clinical need for accessible and reliable testing. The test has a reputable range of 20-130 nmol/mol HbA1C (or 4.0-14 per cent HbA1c).
“Decentralised diabetes testing allows people to go to their GP or pharmacy and have these tests done there. This is important because it allows individuals to see their results immediately and therefore encourages them to achieve the target set out for them. It also enables the healthcare provider to be reassured that the level of improvement or control is a true representation of the metabolic situation,” said Professor Gary John, consultant clinical biochemist for Norfolk and Norwich University Hospital
“Basic laboratory support for clinical colleagues providing healthcare is fundamental; anything that allows our clinical teams to gather the complete information they need on the patient they are dealing with at that point in time is central to good metabolic control,” said John.